T1	intervention 11 26	zoledronic acid
T2	eligibility 54 139	premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer
T3	condition 30 50	bone mineral density
T4	No-of-participants 956 963	Seventy
T5	control 1097 1104	placebo
T6	duration 1109 1118	24 months
T7	outcome-Measure 1141 1196	change in lumbar spine BMD at 24 months versus baseline
T8	outcome-Measure 1227 1269	femoral neck and total femoral BMD changes
T9	outcome-Measure 1271 1285	changes in BTM
T10	outcome-Measure 1291 1297	safety
T12	outcome 1457 1488	Mean changes in T- and Z-scores
T13	outcome 1494 1528	femoral neck and total femoral BMD
T11	outcome 1299 1315	Lumbar spine BMD
T14	outcome 1554 1583	Bone resorption marker levels
T15	outcome 1731 1797	Bone formation marker (procollagen I N-terminal propeptide) levels
T16	adverse-effect 2041 2065	osteonecrosis of the jaw
